Patent 7364736

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Active provider: Google · gemini-2.5-flash

No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.

Cases on file (5)

Group view →

Specific litigation cases in our database that name US patent 7364736. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

✓ Generated

US Patent 7364736, titled "Antibodies to OPGL," has been involved in several patent infringement lawsuits, primarily concerning denosumab biosimilar products.

Here is a summary of the known litigation:

  • Amgen Inc. et al. v. Sandoz Inc. et al.

    • Jurisdiction: District of New Jersey.
    • Case Number: 1:23-cv-02406-CPO-EAP (D.N.J.).
    • Filing Date: May 1, 2023.
    • Outcome/Current Status: This case was resolved through a confidential settlement agreement at the end of April 2024. A court order issued on April 29, 2024, found the asserted claims of US Patent 7364736 to be valid, enforceable, and infringed by Sandoz's denosumab biosimilars in the United States. The settlement allows Sandoz to launch its biosimilar products on May 31, 2025, or earlier under certain limited conditions.

  • Amgen Inc. et al. v. Celltrion, Inc.

    • Jurisdiction: District of New Jersey.
    • Case Number: 1:24-cv-06497-CPO-EAP (D.N.J.).
    • Filing Date: May 2024.
    • Outcome/Current Status: This BPCIA action is currently pending before Judge O'Hearn and Magistrate Judge Pascal, with preliminary expedited discovery proceedings related to 29 asserted patents, including US7364736.

  • Amgen Inc. et al. v. Samsung Bioepis Co., Ltd. et al.

    • Jurisdiction: District of New Jersey.
    • Case Number: 1:24-cv-08417-CPO-EAP (D.N.J.).
    • Filing Date: August 2024.
    • Outcome/Current Status: On January 22, 2026, the District of New Jersey entered a Consent Order and Judgment by stipulation of both parties. For the purposes of this action, the asserted claims of all 21 enumerated patents, including US7364736B2, were deemed valid, enforceable, and infringed by Samsung's making, using, selling, offering to sell, or importing denosumab biosimilar products in the United States and its territories. This consent judgment was entered solely to effectuate a settlement.

  • Amgen Inc. et al. v. Amneal LLC and mAbxience S.A.U.

    • Jurisdiction: District of New Jersey.
    • Case Number: 1:25-cv-17278-CPO-EAP (D.N.J.).
    • Filing Date: November 6, 2025.
    • Outcome/Current Status: Amgen filed this BPCIA action asserting infringement of several patents, including US Patent 7364736, against Amneal LLC and mAbxience S.A.U. for their proposed denosumab biosimilar products. This case is currently ongoing.

Additionally, Unified Patents indicates several other cases filed in the New Jersey District Court and one in the Massachusetts District Court involving US7364736, though detailed outcomes are not provided in the readily available snippets. These include:

  • 1:25-cv-12160 (New Jersey District Court)
  • 1:25-cv-11867 (Massachusetts District Court)
  • 1:25-md-03138 (New Jersey District Court)
  • 1:25-cv-17596 (New Jersey District Court)
  • 1:25-cv-13358 (New Jersey District Court)
  • 1:25-cv-01305 (New Jersey District Court)
  • 1:25-cv-12152 (New Jersey District Court)
  • 1:24-cv-08417 (New Jersey District Court)
  • 1:24-cv-06497 (New Jersey District Court)

Generated 5/29/2026, 8:40:34 PM